MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/blood-2010-11-317073

Медицинская библиотека · Blood · 2011

Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC.

Sutton Laurent, Chevret Sylvie, Tournilhac Olivier, Diviné Marine, Leblond Véronique, Corront Bernadette, Leprêtre Stéphane, Eghbali Houchingue, Van Den Neste Eric, Michallet Mauricette, Maloisel Frédéric, Bouabdallah Krimo, Decaudin Didier, Berthou Christian, Brice Pauline, Gonzalez Hugo, Chapiro Elise, Radford-Weiss Isabelle, Leporrier Nathalie, Maloum Karim, Nguyen-Khac Florence, Davi Frédéric, Lejeune Julie, Merle-Béral Hélène, Leporrier Michel, Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and Groupe Français d'étude de la Leucémie Lymphoïde Chronique (GFLLC)

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Long-term responses have been reported after autologous stem cell transplantation (ASCT) for chronic lymphocytic leukemia (CLL). We conducted a prospective, randomized trial of ASCT in previously untreated CLL patients. We enrolled 241 patients < 66 years of age with Binet stage B or C CLL. They received 3 courses of mini-CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone/prednisolone) and then 3 courses of fludarabine. Patients in complete response (CR) were then randomized to ASCT or observation, whereas the other patients were randomized to dexamethasone, high-dose aracytin, cisplatin (DHAP) salvage followed by either ASCT or 3 courses of fludarabine plus cyclophosphamide (FC). The primary end point was event-free survival (EFS). After up-front treatment, 105 patients entered CR and were randomized between ASCT (n = 52) and observation (n = 53); their respective 3-year EFS rates were 79.8% and 35.5%; the adjusted hazard ratio was 0.3 (95% CI: 0.1-0.7; P = .003). Ninety-four patients who did not enter CR were randomized between ASCT (n = 46) and FC (n = 48); their respective 3-year EFS rates were 48.9% and 44.4%, respectively; the adjusted hazard ratio was 1.7 (95% CI: 0.9-3.2; P = .13). No difference in overall survival was found between the 2 response subgroups. In young CLL patients in CR, ASCT consolidation markedly delayed disease progression. No difference was observed between ASCT and FC in patients requiring DHAP salvage.

Для цитирования: Sutton Laurent, Chevret Sylvie, Tournilhac Olivier, Diviné Marine, Leblond Véronique, Corront Bernadette, Leprêtre Stéphane, Eghbali Houchingue, Van Den Neste Eric, Michallet Mauricette, Maloisel Frédéric, Bouabdallah Krimo, Decaudin Didier, Berthou Christian, Brice Pauline, Gonzalez Hugo, Chapiro Elise, Radford-Weiss Isabelle, Leporrier Nathalie, Maloum Karim, Nguyen-Khac Florence, Davi Frédéric, Lejeune Julie, Merle-Béral Hélène, Leporrier Michel, Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and Groupe Français d'étude de la Leucémie Lymphoïde Chronique (GFLLC). Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC.. Blood. 2011. DOI: 10.1182/blood-2010-11-317073.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.